Perioperative treatment for gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding the immunotherapy drug pucotenlimab to chemotherapy before and after surgery for locally advanced gastroesophageal junction cancer. The goal is to see if this combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with gastroesophageal junction cancer that can be surgically removed.
- You are between 18 and 75 years old.
- You have not received any prior treatment for this cancer, such as chemotherapy, radiation, or immunotherapy.
- You have an ECOG performance status of 0 or 1 (fully active or only slightly limited).
- Your organ function (kidney, liver, bone marrow) meets specific blood test criteria.
- You agree to use effective birth control during and for a period after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Gastroesophageal Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.